Author

A. Baris

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

E. Fraile-Bethencourt· 2 shared R. Ruhl· 2 shared S. Anand· 2 shared S. Khou· 2 shared B. J. Druker· 1 shared B. M. Smith· 1 shared C. Espinosa-Diez· 1 shared G. L. Kong· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Fraile-Bethencourt

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumor cell intrinsic RIG-I activation co-opts the host microenvironment to drive immune mediated tumor rejection

E. Fraile-Bethencourt, S. Khou, A. Baris, R. Ruhl, S. Anand

This study shows that activating RIG-I in tumor cells enhances anti-tumor immunity and improves response to checkpoint therapy, suggesting a strategy for cancer vaccines.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

DNA damage-induced lncRNA MEG9 impacts angiogenesis

E. Fraile-Bethencourt, S. Khou, R. Wilson, A. Baris, R. Ruhl, C. Espinosa-Diez, S. Anand

This study identifies MEG9 as a cytoprotective lncRNA in endothelial cells that modulates angiogenesis and vascular homeostasis in response to DNA damage.

bioRxiv · Dec 7, 2022 · PreprintCell Biology

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

S. A. Carratt, G. L. Kong, B. M. Smith, Z. Schonrock, L. Maloney, A. Baris, B. J. Druker, T. P. Braun, J. E. Maxson

This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.

bioRxiv · Nov 4, 2021Cancer Biology